CXCR4 and acute myeloid leukemia: In vivo, subcutaneous injections of BKT140 (a new-generation peptide CXCR4 inhibitor) significantly reduced the growth of human acute myeloid leukemia in a dose-dependent manner (Beider et al., 2011).